Teva launches generic Aprovel in UK

30 August 2012

The UK subsidiary of Israel’s Teva Pharmaceutical Industries (NYSE: TEVA), the world’s largest generic drugmaker, yesterday announced the launch of generic Irbesartan tablets in the UK. Irbesartan is a generic version of Aprovel from France’s Sanofi (Euronext: SAN) and USA-based Bristol-Myers Squibb (NYSE: BMY).

The drug is indicated in the treatments of essential hypertension and renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

Irbesartan tablets are available in Britain immediately in the Teva 360 livery as follows:

   Strength                      75mg          150mg        300mg
   Pack size                       28                28              28
   Brand Price                   £9.69         £11.84       £15.93
   Initial Teva price            £2.42          £2.96        £3.98

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK